Protagonist Therapeutics, Inc. (NASDAQ:PTGX) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Headlines Articles Press releases Protagonist Therapeutics, Inc.

Home
Companies
Protagonist Therapeutics, Inc.

BRIEF

published on 11/27/2025 at 09:50, 7 days 20 hours ago

Protagenic Therapeutics Faces Nasdaq Non-Compliance Notice

Delisting NASDAQ Non-compliance Stockholders' Equity Quarterly Report Delay Protagenic Therapeutics
PRESS RELEASE

published on 11/27/2025 at 09:45, 7 days 20 hours ago

Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
Protagenic Therapeutics, Inc. receives notice of non-compliance with Nasdaq Listing Rules, takes steps for delisting appeal. Stock to continue trading during the process

Nasdaq Listing Stock Trading Delisting Non-Compliance Protagenic Therapeutics
BRIEF

published on 11/06/2025 at 22:10, 28 days 8 hours ago

Protagonist Therapeutics Reports Q3 2025 Financial Results and Highlights Advancements

Financial Results Pipeline Development Rusfertide NDA Submission Icotorinra
PRESS RELEASE

published on 11/06/2025 at 22:05, 28 days 8 hours ago

Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Protagonist Therapeutics reports financial results and updates on NDA submissions for icotrokinra and rusfertide, as well as progress in clinical trials for PN-881 and IND-enabling studies for PN-477sc and PN-477o

Financial Results Clinical Trials Protagonist Therapeutics IND-enabling Studies NDA Submissions
BRIEF

published on 11/03/2025 at 22:10, 1 month 1 day ago

Protagonist Therapeutics Highlights Rusfertide at ASH Meeting

Clinical Data Protagonist Therapeutics Rusfertide Polycythemia Vera ASH Meeting 2025
PRESS RELEASE

published on 11/03/2025 at 22:05, 1 month 1 day ago

Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting
Protagonist Therapeutics to present rusfertide clinical data at ASH Annual Meeting 2025. Focus on VERIFY study results in polycythemia vera

Clinical Data Protagonist Therapeutics Rusfertide Polycythemia Vera ASH Annual Meeting
BRIEF

published on 10/27/2025 at 12:40, 1 month 8 days ago

Protagonist Therapeutics Releases Promising Data on Icotrokinra

Ulcerative Colitis Clinical Trials Protagonist Therapeutics Plaque Psoriasis Icotrokinra
PRESS RELEASE

published on 10/27/2025 at 12:35, 1 month 8 days ago

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences
Protagonist Therapeutics, Inc. announces positive clinical outcomes for icotrokinra in ulcerative colitis and psoriasis at medical conferences. Study data support Phase 3 development for various inflammatory conditions

Ulcerative Colitis Phase 3 Protagonist Therapeutics Psoriasis Icotrokinra
BRIEF

published on 10/07/2025 at 14:15, 1 month 28 days ago

Protagonist Therapeutics Reports Promising Data for Icotrokinra in Ulcerative Colitis

Ulcerative Colitis Clinical Trials Phase 2b Study Protagonist Therapeutics Icotrokinra
PRESS RELEASE

published on 10/07/2025 at 14:10, 1 month 28 days ago

Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill
Icotrokinra meets primary clinical endpoints in Phase 2b study for ulcerative colitis treatment, showing promising results at Week 12. Phase 3 trials expected to start in Q4 2025

Ulcerative Colitis Phase 3 Trial Phase 2b Study Protagonist Therapeutics Icotrokinra

1 2 ... 8

Accesswire

Published on 12/05/2025 at 02:35, 3 hours 35 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 3 hours 40 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 5 hours 10 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 5 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 10 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 2 hours 40 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 19 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 45 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 55 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 59 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 12 hours 10 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 25 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 26 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 9 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE